Category Archives: New York Stem Cells

Equities researchers at William Blair started coverage on shares of Century Therapeutics (NASDAQ:IPSC Get Rating) in a report issued on Thursday, The Fly reports. The brokerage set a market perform rating on the stock.

A number of other research firms have also recently issued reports on IPSC. SVB Leerink reissued a buy rating and issued a $32.00 target price on shares of Century Therapeutics in a research note on Friday, March 18th. Zacks Investment Research raised Century Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the companys stock. According to data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $36.00.

NASDAQ:IPSC traded up $0.02 on Thursday, reaching $8.10. The companys stock had a trading volume of 211 shares, compared to its average volume of 110,036. Century Therapeutics has a 1-year low of $7.32 and a 1-year high of $32.90. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.03. The businesss 50-day moving average price is $12.10 and its two-hundred day moving average price is $14.49.

A number of large investors have recently modified their holdings of IPSC. Citigroup Inc. acquired a new stake in Century Therapeutics during the third quarter worth approximately $34,000. Royal Bank of Canada acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $35,000. New York State Common Retirement Fund acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $53,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $94,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $134,000. 57.50% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics (Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

Featured Articles

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
William Blair Begins Coverage on Century Therapeutics (NASDAQ:IPSC) - Defense World

Neurodegenerative diseases are defined by an increasingly widespread and debilitating death of nervous system cells, but they also share other grim characteristics: Their cause is rarely discernible and they have all eluded cures. To spur fresh, promising approaches and to encourage new experts and expertise to join the field, MITs Aging Brain Initiative (ABI) this month awarded five seed grants after a competition among labs across the Institute.

Founded in 2015 by nine MIT faculty members, the ABI promotes research, symposia, and related activities to advance fundamental insights that can lead to clinical progress against neurodegenerative conditions, such as Alzheimers disease, with an age-related onset. With an emphasis on spurring research at an early stage before it is established enough to earn more traditional funding, the ABI derives support from philanthropic gifts.

Solving the mysteries of how health declines in the aging brain and turning that knowledge into effective tools, treatments, and technologies is of the utmost urgency given the millions of people around the world who suffer with no meaningful treatment options, says ABI director and co-founder Li-Huei Tsai, the Picower Professor of Neuroscience in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences. We were very pleased that many groups across MIT were eager to contribute their expertise and creativity to that goal. From here, five teams will be able to begin testing their innovative ideas and the impact they could have.

To address the clinical challenge of accurately assessing cognitive decline during Alzheimers disease progression and healthy aging, a team led by Thomas Heldt, associate professor of electrical and biomedical engineering in the Department of Electrical Engineering and Computer Science (EECS) and the Institute for Medical Engineering and Science, proposes to use artificial intelligence tools to bring diagnostics based on eye movements during cognitive tasks to everyday consumer electronics such as smartphones and tablets. By moving these capabilities to common at-home platforms, the team, which also includes EECS Associate Professor Vivienne Sze, hopes to increase monitoring beyond what can only be intermittently achieved with high-end specialized equipment and dedicated staffing in specialists offices. The team will pilot their technology in a small study at Boston Medical Center in collaboration with neurosurgeon James Holsapple.

Institute Professor Ann Graybiels lab in the Department of Brain and Cognitive Sciences (BCS) and the McGovern Institute for Brain Research will test the hypothesis that mutations on a specific gene may lead to the early emergence of Alzheimers disease (AD) pathology in the striatum. Thats a a brain region crucial for motivation and movement that is directly and severely impacted by other neurodegenerative disorders including Parkinsons and Huntingtons diseases, but that has largely been unstudied in Alzheimers. By editing the mutations into normal and AD-modeling mice, Research Scientist Ayano Matsushima and Graybiel hope to determine whether and how pathology, such as the accumulation of amyloid proteins, may result. Determining that could provide new insight into the progression of disease and introduce a new biomarker in a region that virtually all other studies have overlooked.

Numerous recent studies have highlighted a potential role for immune inflammation in Alzheimers disease. A team led by Gloria Choi, the Mark Hyman Jr. Associate Professor in BCS and The Picower Institute for Learning and Memory, will track one potential source of such activity by determining whether the brains meninges, which envelop the brain, becomes a means for immune cells activated by gut bacteria to circulate near the brain, where they may release signaling molecules that promote Alzheimers pathology. Working in mice, Chois lab will test whether such activity is prone to increase in Alzheimers and whether it contributes to disease.

A collaboration led by Peter Dedon, the Singapore Professor in MITs Department of Biological Engineering, will explore whether Alzheimers pathology is driven by dysregulation of transfer RNAs (tRNAs) and the dozens of natural tRNA modifications in the epitranscriptome, which play a key role in the process by which proteins are assembled based on genetic instructions. With Benjamin Wolozin of Boston University, Sherif Rashad of Tohoku University in Japan, and Thomas Begley of the State University of New York at Albany, Dedon will assess how the tRNA pool and epitranscriptome may differ in Alzheimers model mice and whether genetic instructions mistranslated because of tRNA dysregulation play a role in Alzheimers disease.

With her seed grant, Ritu Raman, the dArbeloff Assistant Professor of Mechanical Engineering, is launching an investigation of possible disruption of intercellular messages in amyotrophic lateral sclerosis (ALS), a terminal condition in which motor neuron causes loss of muscle control. Equipped with a new tool to finely sample interstitial fluid within tissues, Ramans team will be able to monitor and compare cell-cell signaling in models of the junction between nerve and muscle. These models will be engineered from stem cells derived from patients with ALS. By studying biochemical signaling at the junction the lab hopes to discover new targets that could be therapeutically modified.

Major support for the seed grants, which provide each lab with $100,000, came from generous gifts by David Emmes SM 76; Kathleen SM 77, PhD 86 and Miguel Octavio; the Estate of Margaret A. Ridge-Pappis, wife of the late James Pappis ScD 59; the Marc Haas Foundation; and the family of former MIT President Paul Gray 54, SM 55, ScD 60, with additional funding from many annual fund donors to the Aging Brain Initiative Fund.

Read more here:
Aging Brain Initiative awards fund five new ideas to study, fight neurodegeneration - MIT News

NEW YORK and HONG KONG, April 26, 2022 /PRNewswire/ --Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML).

"Although several exciting new classes of medicines have emerged in the past decade for patients with AML, there still remains an unmet need for certain patient segments, where survival rates remain low," said Dr. Michael Tusche, Treadwell co-CEO. "CFI-400945, has shown encouraging signs of monotherapy activity in AML patients with adverse cytogenetics. We are grateful for the Fast Track Designation for this exciting program, and look forward to frequent interactions with the FDA to chart our regulatory path forward, as we continue the development of '945 in leukemia."

Fast Track designation seeks to streamline the development and accelerate the review of new agents with potential to treat serious or life-threatening diseases and that potentially address an unmet medical need. Drugs that are granted this designation can have more frequent interactions with the FDA, as well as potential pathways for expedited approval.

About AML

AML is a disease characterized by uncontrolled proliferation of malignant clonal hematopoietic stem cells which can lead to anemia, neutropenia, and thrombocytopenia. If left untreated, AML can lead to death within weeks. In the US, an estimated 19,940 new cases of AML were expected to be diagnosed and approximately 11,180 deaths attributed to AML, nearly all in adults. AML is generally a disease of the elderly with an average age of 68 years at the time of diagnosis and is more common in men than women. For adults <65 years of age, the 5-year survival is approximately 33%, but drops dramatically to 4% in adults >65 years of age.

About Treadwell TherapeuticsTreadwell Therapeutics is a clinical-stage multi-modality oncology company developing novel medicines to address unmet needs in patients with cancer. The Company's robust, internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor). Treadwell also has a robust pre-clinical pipeline with multiple biologic and next generation TCR based autologous cell therapy programs. For more information, please visit http://www.treadwelltx.com.

Contact[emailprotected]

SOURCE Treadwell Therapeutics

Visit link:
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia - PR Newswire

A good hair day can bolster your confidence or, conversely, leave you feeling less than your best. Its no surprise interest for professional hair services is rising yet again, according to Spate research: Searches for hair salons are growing by almost 12 percent since last year and there are 4.2 million inquiries for hair services on an average monthly basis.

But the hunt is over. Whether youre shopping for a dye-coated life change, need some inspiration before your next salon visit or are considering investing in your hairs health once and for all, heres whats trending now in the world of transformative hair treatments.

It may be among the most straightforward ways to transform your hair, but the power of a cut and color should not be discounted. Your haircut and color is a frame to your personal image, says R+Co Collective member and colorist Richy Kandasamy. Transforming your hair can be a whole life-changing moment. As showcased in Kandasamys clients dramatic transformation, sharp angles and show-stopping cuts are currently trending. (Pinterest searches for mullet hairstyles have increased 190 percent and inquiries for shaved head dye designs are up 12x since last year.)

Before coloring Ashleys hair, we started with the undercut to help visualize the end result. After assessing her style, personality, complexion and eye level, we were able to choose the perfect color, says Kandasamy. He then pre-lightened her hair using a powder lightener, then toned with a demi-permanent haze blonde color.

Pantones color of the year may be lilac-hued Veri Peri, but when it comes to hair, 2022 is all about brunette tones, natural-looking dimension and 70s blondes. Celebrity colorist Chad Kenyon is known for his lived-in color jobs, and says even subtle changes make a huge impact to those in his chair. Ive had clients cry tears of joy by seeing how hair color has changed the way they see themselves, he says. Kenyon explains he paints hair in such a way that he is able to carefully enhance and diffuse facial features.

Kenyon enhanced this clients auburn hair by adding dimension and faceframing highlights with a natural, lived-in blonde color.

Not ready for a color change or dramatic cut? Adding length and volume to your hair with professional- grade extensions can be just as transformative. Our stylists address our clients hair challenges and identify ways that our extensions can be a tool used to help fix the challenge, says Jennifer Martin, director of marketing for Great Lengths.

I have worn Great Lengths bonded extensions for over 15 years and its given me the confidence I needed to walk through the world as a business woman without worrying about my hair, says this client styled by Marie Green of Hair Extensions by Marie. Its as easy as getting cosmetic filler and it takes my fine, limp hair to a level of confident, powerful and celebrity- worthy locks in one application.

Green applied 18-inch premium keratin-bonded strands from Great Lengths in a variety of colors for a seamless blend.

Because many keratin treatments contain formaldehyde or formaldehyde-releasing chemicalsbe sure to ask your stylist for the specifics on your formula if youre a keratin- userlong-term use of the in-salon treatment can wreak havoc on your strands and leave you with dry, brittle and severely damaged hair over time.

Lorraine Massey of Spiral XYZ salon has made nursing clients hair back to health her mission. My goal is to help clients who have had their hair damaged after years of chemical treatments, she says. Her focus while bringing curl patterns back to life: education, patience and hydration. Once you care for the hair you have and start seeing the health and growth evidence, there is no going back.

Scheduled touch-ups and bleach jobs can do a number on once strong, resilient strands.

Olaplexs latest in-salon innovation, the 4-in-1 Moisture Mask, penetrates the hair shaft to repair damaged, broken bonds after a chemical service. The highly concentrated mask includes elevated levels of ceramides, oils and amino acids to add shine, tame unruly strands and deliver intense moisture to dry hair in need of TLC.

The collagen-rejuvenating power of microneedling with platelet-rich plasma can deliver transformative results when used on the scalp. So much so, Wayne, NJ facial plastic surgeon Jeffrey B. Wise, MD likens the treatment to fertilizer for hair. Microneedling with PRP stimulates the stem cells in the hair root, awakening the scalp and pushing any dormant follicles into growth mode, explains Dr. Wise. We are waking up the hair and giving it the nourishment it needs to start thriving again. PRP is an excellent preventative option for those noticing hair thinning, or anyone with a family history of hair loss over time. However, Dr. Wise notes PRP cannot grow hair in areas where follicles no longer exist, so someone experiencing advanced balding will more likely be a candidate for a hair transplant.

Glenn Dale, MD dermatologist Valerie Callender, MD says in-office hair-loss treatments like microneedling with PRP are often used in combination with nutraceuticals such as Nutrafol or Viviscal to usher in optimal results.

To jump-start growth, its best to target follicles during each of the three hair growth and shedding phases. This requires three sessions of PRP therapy, spaced four to six weeks apart, says Dr. Wise. In the best case scenario, patients would also keep up with maintenance sessions every six months to ensure hair stays healthy.

This 61 year old female complained of hair thinning on her scalp for several years. Along with taking Viviscal Professional Hair Vitamins, Dr. Callender performed three sessions of PRP injections spaced four weeks apart.

The Fotona laser is an ablative skin-resurfacing laser commonly used to achieve a brighter, smoother complexion. It can also be used for skin-tightening and off-the-face plumping. Used off label, New York dermatologist Doris Day, MD has found huge success in the laser beams ability to significantly revive hair follicles on the scalp.

Dr. Day says the laser works through a mechanism of photobiomodulation, where heat and energy are used to stimulate and revive stem cells of the follicle, as well as to stabilize the follicle itself. The Fotona laser can be used to treat many different forms of hair lossDr. Day notes she has seen success in both autoimmune and genetic casesand 12 treatment sessions spaced two weeks apart, are generally recommended, followed by maintenance treatments at three months.

Dr. Day performed multiple treatments of Fotona Hairlase in order to address this 54 year old females hair-loss concerns.

The only permanent solution to hair loss, hair restoration surgery (also known as a hair transplant) involves taking a viable hair graft or follicle from one part of the body and placing it in a different part, most commonly the scalp, says Delray Beach, FL facial plastic surgeon Miguel Mascar, MD.

There are two methods of extracting the grafts: FUT, or strip technique, and FUE, or follicular unit extraction technique, where the grafts are removed one by one. Dr. Wise says most patients prefer the FUE technique as its the least invasive and doesnt leave a linear scar. The best part is the natural-looking result: The transplanted hair will continue growing as if it has always been there, he says.

Candidacy relies on the location and nature of hair loss, but the best candidates for the surgery are those that have a good donor area, and have realistic expectations based on their goals and desires, says Dr. Mascar.

This 29-year-old patient opted for a FUE hair transplant with Dr. Wise. 2,500 grafts were transplanted to the top and sides of her scalp. Results shown at the six-month post-op mark.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read the original post:
What's Trending in the World of Hair Treatments - NewBeauty Magazine

Companies Profiled in U.S. Animal Model Market are Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Inc., Genoway, Envigo (Inotiv, Inc.), Marshall BioResources, Janvier Labs, Applied stem cells, Biocytogen, Transposagen Biopharmaceuticals, Inc. (Hera Bio Labs), Cyagen, Ingenious targeting labs, Crown Bioscience Inc. (JSR Corporation)., Harbour Biomed, Sinclair Bio Resources, Alpha Genesis Inc., Creative Animodel, DaVinci Biomedical Research Products, Inc

NEWARK, Del., April 27, 2022 /PRNewswire/ -- As per Future Market Insights' latest industry analysis, the U.S. animal model market was valued at over US$ 921.9 Mn in 2021 and is anticipated to exhibit a CAGR of close to 4.1% over the forecast period (2022-2032).

Animal models are predominantly used to gather information regarding the disease and its prevention, diagnosis, and treatment. They are being used to resolve a wide range of scientific concerns, ranging from basic science to the discovery and evaluation of new vaccines and therapies. Animals are used because of the similarities in biology across most mammals.

Personalized medicine is also known as precision medicine which utilizes data about a specific patient or an individual's genes to plan treatment for a disease. Animal models can play important role in the development of new approaches for personalized medicine. Increasing adoption of personalized medicine will drive sales of animal model in the forthcoming years.

Toxicity testing in animals is done to discover potential side effects from an agent's exposure and to generate dose-response relationships. Animal testing is important for the early detection of the potential risk to humans or as models to study the causes, pathogenesis, progression, and treatment of diseases.

Request for PDF [emailprotected] https://www.futuremarketinsights.com/reports/sample/rep-gb-14527

Organizations and legislations such as the Federal Food, Drug, and Cosmetic Act (FFDCA), Environmental Protection Agency (EPA), Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), and Organization for Economic Co-operation and Development (OECD) determine the testing guidelines for toxicity testing on animals.

Some factors such as the high production volume of chemicals testing in the U.S., increasing generation and utilization of novel GM animal strains in toxicity studies, and the development and attempted validation of several animal tests to screen chemicals for endocrine (hormone)-disrupting activity are expected to drive the growth in the market.

"Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing applications of animal model for more predictive outcomes, and ongoing innovations in animal models will augment the growth in the market over the forecast period,"says an FMI analyst.

Key Takeaways:

To Remain 'Ahead' of Your Competitors, Get Customized [emailprotected] https://www.futuremarketinsights.com/customization-available/rep-gb-14527

Market Competition

Key players operating in the U.S. animal model market are expanding their business through partnerships and acquisitions with other companies to improve their global footprint. Following are a few examples of acquisitions:

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the animal model market in its latest study, presenting a historical demand assessment of 20172021 and projections for 2022 2032.

Contact Sales for Further Assistance in Purchasing this [emailprotected]https://www.futuremarketinsights.com/checkout/14527

The research study is based on the species (rats, mice, pigs, rabbits, monkeys, dogs, cats, other species), therapeutics- (metabolic diseases, cardiovascular diseases, neurological diseases, and oncology), application (drug discovery/development and basic & applied research) end-user (academic & research institutes, pharmaceutical companies, biotechnology companies, and CROs) and across seven key regions of the world.

Top Reports Related to HealthcareMarket Insights

Private office-based clinics Market: The global private office-based clinics market is anticipated to grow at a moderate CAGR during the forecast period from 2022 and 2032.

Coronary Artery Bypass Grafts Market: The coronary artery bypass graft market size was valued at USD 16.5 billion in 2020 and is expected grow with a CAGR of 6.1% during the forecast period.

Oligonucleotide API Market:Oligonucleotide API Market is witnessing high uptake of Antisense oligonucleotide (ASO) therapeutics. What other key factors will drive growth through 2030?

About Future Market Insights (FMI)

Future Market Insights(ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-845-579-5705For Sales Enquiries:[emailprotected]Website:https://www.futuremarketinsights.comReport: https://www.futuremarketinsights.com/reports/u-s-animal-model-marketLinkedIn|Twitter|Blogs

SOURCE Future Market Insights

See the article here:
Demand in the US Animal Model Market is set to Increase at a 4.1% CAGR from 2022 to 2032 - Future Market Insights - PR Newswire

-Potential for up to $452 million in milestone payments with royalties in the mid-twenty percent range

-Actinium receives $35 million upfront payment

-Immedica obtains exclusive rights to Iomab-B in Europe, the Middle East and North Africa

NEW YORK and STOCKHOLM, April 12, 2022 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, and Immedica Pharma AB ("Immedica") today announced entering a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies. A pivotal Phase 3 trial, Study of Iomab-B versus Conventional Care in Elderly, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA), of Iomab-B completed patient enrollment in the third quarter of 2021 with topline data expected in the third quarter of 2022. BMT is the only potentially curative treatment option for patients with active, relapsed or refractory acute myeloid leukemia (AML).

Sandesh Seth, Actinium's Chairman and CEO, said, "Immedica has established a strong team and impressive capabilities to commercialize specialty products in Europe, the Middle East and North Africa. Europe and the MENA countries are key commercial markets for Iomab-B, with a large addressable AML patient population and access to a strong BMT community that is highly concentrated with select leading centers performing a majority of the BMT procedures. Despite multiple drug approvals for patients with AML in recent years, curative outcomes and access to potentially curative BMT are severely lacking, particularly for patients with active, relapsed or refractory disease. We are excited to partner with Immedica to work to bring Iomab-B to patients with AML in Europe, the Middle East and North Africa who may benefit from a potentially curative transplant."

"We are excited about the opportunity to make Iomab-B accessible for patients in Europe, the Middle East and North Africa. It is clear there is a large medical need for these AML patients, which we believe will be addressed by this new innovative treatment. We also look forward to deepening our collaboration with Actinium to bring the best possible support to AML treatment centers and health care professionals in Europe, the Middle East and North Africa", says Anders Edvell, CEO at Immedica.

Under the terms of the agreement, Actinium will receive an upfront payment of $35 million and will be eligible to receive an additional $417 million in regulatory and commercial milestones as well as royalties in the mid-twenty percent range on net sales. Immedica receives commercialization rights in Europe and MENA countries. Actinium retains all rights related to Iomab-B in the United States and the rest of the world, and will be responsible for certain clinical and regulatory activities and the manufacturing of Iomab-B.

Shadow Lake Group (SLG) served as the advisor to Immedica.

About Iomab-BIomab-B (I-131 apamistamab), via the monoclonal antibody apamistamab, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, immune cells and bone marrow stem cells. Apamistamab is linked to the radioisotope iodine-131 (I-131) and once attached to its target cells emits energy that travels about 100 cell lengths, destroying a patient's cancer cells and ablating their bone marrow. By carrying iodine-131 directly to the bone marrow in a targeted manner, Iomab-B may avoid the side effects of non-targeted chemotherapy and external radiation on most healthy tissues while effectively killing the patient's cancer (induction) and marrow cells (myeloablation) including those in bone marrow niches due to the "crossfire" effect enabled by the I-131 radioisotope.

Iomab-B was licensed from the Fred Hutchinson Cancer Research Center where it was studied in nearly 300 patients, in multiple clinical trials in 6 blood cancer indications. Iomab-B is being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with active, relapsed or refractory Acute Myeloid Leukemia (AML) who are age 55 and above. If granted approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, in a potentially more efficacious manner and with a more beneficial safety profile than the non-targeted intensive chemotherapy conditioning that is the current standard of care in bone marrow transplant conditioning. A bone marrow transplant is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Iomab-B has been granted Orphan Drug Designation from the U.S. FDA and the European Medicines Agency (EMA). Iomab-B also has patent terms extending to at least 2036/2037 in the US and EU. In addition, Actinium received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the EMA indicating that the Phase 3 SIERRA trial design, primary endpoint and planned statistical analysis are acceptable as the basis for a Marketing Authorization Application.

About the SIERRA Phase 3 TrialThe SIERRA trial is a 150-patient, randomized clinical trial, studying Iomab-B compared to physician's choice of salvage therapy in patients with active, relapsed or refractory acute myeloid leukemia (r/r AML) age 55 and above. The SIERRA trial completed enrollment in the third quarter of 2021 with the last patient receiving a BMT in the fourth quarter of 2021. Topline data from the SIERRA trial is expected in the third quarter of 2022. In SIERRA, patients receiving Iomab-B, those achieving a remission after salvage therapy or those patients not achieving remission after salvage therapy that crossed over to receive Iomab-B were offered a BMT, which is the only treatment option with curative potential for patients with active r/r AML. The SIERRA trial is the only randomized Phase 3 trial to offer BMT to this patient population. The control arm of SIERRA included over 20 single agents or combination treatment options based on physician's choice, including salvage chemotherapy and recently approved targeted agents including Bcl-2 inhibitor (Venetoclax), FLT3 inhibitors and IDH 1/2 inhibitors as there is no standard of care for this patient population. The SIERRA trial enrolled patients at 24 leading transplant centers in the United States and Canada.

About Actinium Pharmaceuticals, Inc.Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs not addressed by traditional cancer therapies. Actinium's current clinical pipeline is led by ARCs or Antibody Radiation-Conjugates that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Actinium's targeted conditioning ARCs seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) has been studied in over four hundred patients including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning that complete patient enrollment in the third quarter of 2021. Topline data from the SIERRA trial is expected in the third quarter of 2022. Iomab-ACT, low dose I-131 apamistamab is being studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center. In addition, we are leaders in the field of Actinium-225 alpha therapies. Actimab-A, our clinical stage CD33 targeting ARC alpha therapy has been studied in nearly 150 patients including our ongoing combination trials with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 170 patents and patent applications, know-how, collective research and expertise in the field are leveraged to design and study novel targeted radiotherapies and combinations to strategically bolster our pipeline. Our AWE technology platform is currently being utilized in collaborative research partnerships with Astellas Pharma, Inc. for solid tumor theranostics, with AVEO Oncology to create an Actinium-225 HER3 targeting radiotherapy for solid tumors, and with EpicentRx, Inc.to create targeted radiotherapy combinations with their novel, clinical stage small molecule CD47-SIRP inhibitor. Website: https://www.actiniumpharma.com/

About Immedica ABImmedica is a fast-growing private niche pharma group with its headquarter in Stockholm, Sweden, and commercial coverage across Europe and the Middle East. Immedica has significant know-how and experience in commercialization of specialty care products across Europe and the Middle East, and the company's management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality assurance and product distribution.

More information is available at http://www.immedica.com

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Actinium Contacts

Investors:Hans VitzthumLifeSci Advisors, LLC[emailprotected](617) 430-7578

Immedica Contacts

Chief Executive OfficerAnders EdvellImmedica Pharma AB[emailprotected]+46 (0)70 544 6126

SOURCE Actinium Pharmaceuticals, Inc.

Originally posted here:
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North...

NEW YORK, March 22, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) on March 11, 2022. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting. Preclinical studies have demonstrated that HT-KIT induces apoptosis of neoplastic mast cells and reduces metastasis associated with aggressive mastocytosis.

(PRNewsfoto/Hoth Therapeutics Inc.)

Hoth has successfully completed manufacturing feasibility of the HT-KIT drug substance in collaboration with WuXi STA. Hoth plans to pursue a Pre-IND meeting with FDA by the end of 2022.

"With this important step now completed, Hoth has moved drug development into the later stage which will yield us our clinical formulation and allow us to hold our Pre-IND meeting with the FDA this year," stated Robb Knie, Chief Executive Officer of Hoth.

About HT-KIT

HT-KIT is a new molecular entity (NME) under development for treatment of mast cell derived cancers and anaphylaxis. HT-KIT was developed Dr. Glenn Cruse, Assistant Professor at North Carolina State University and shares the same molecular class as Hoth's current HT-004 drug. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit https://ir.hoththerapeutics.com/.

Story continues

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:LR Advisors LLCEmail: investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-it-has-successfully-completed-manufacturing-feasibility-of-the-ht-kit-drug-substance-301507663.html

SOURCE Hoth Therapeutics, Inc.

Read more:
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance - Yahoo Finance

SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. Center for Medicare and Medicaid Services (CMS).

This new CMS code to be submitted by hospitals performing the CardiAMP cell therapy procedure is available April 1, 2022. The code provides clear reimbursement for the study procedure performed for both the treatment and control arms for the ongoing cell therapy pivotal trials in two cardiovascular indications: the CardiAMP Cell Therapy Heart Failure Trial (NCT02438306) and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NCT03455725).

This most recent action by CMS further represents its commitment to improving the way ischemic heart failure is treated and is supportive of BioCardias therapeutic investigational product candidates furnished by a comprehensive approach to bone marrow cell harvest, processing, and delivery in a single procedure, commented Peter Altman, Ph.D., BioCardias CEO. Further, it provides additional clarity of CMS financial support for institutions conducting the CardiAMP Cell Therapy Heart Failure Trial and CardiAMP Chronic Myocardial Ischemia Trials. We are grateful for our ongoing collaboration with both CMS and the FDA as we continue to demonstrate the promise of our technology.

The new reimbursement code (designated C9782) is for a blinded procedure for New York Heart Association (NYHA) class ii or iii heart failure, or Canadian Cardiovascular Society (CCS) class iii or iv chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory service and all imaging with or without guidance, performed in approved investigational device exemption (IDE) study.

Patients interested in learning about the CardiAMP Cell Therapy Trials can visit http://www.cardiamp.comor http://www.clinicaltrials.govfor more information.

About the CardiAMP Cell Therapy ProgramCardiAMP Cell Therapyuses a patients own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the bodys natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes.CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention. CAUTION - Limited by United States law to investigational use.

About BioCardiaBioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's current products include the Helix transendocardial delivery system, the Morph steerable guide and sheath catheter portfolio and the AVANCE steerable introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. The CardiAMP Cell Therapy Heart Failure Trial has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services. For more information visit: http://www.BioCardia.com.

Forward Looking Statements:This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. These forward-looking statements include, without limitation, statements relating to study enrollment expectations and the likelihood of safety and patient benefit, and ultimate success of our clinical cell therapy programs.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on March 30, 2021, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

INVESTOR CONTACT:David McClung, Chief Financial Officerinvestors@BioCardia.com(650) 226-0120

MEDIA CONTACT:Anne Laluc, MarketingEmail:alaluc@bioCardia.comPhone: 650-226-0120

Read the rest here:
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure - GlobeNewswire

NEW YORK & SEATTLE--(BUSINESS WIRE)--Emendo Biotherapeutics, a next-generation CRISPR biotech expanding the reach of gene editing therapeutics, and Seattle Childrens Research Institute today announced a research collaboration to investigate how hematopoietic stem cells (HSCs) extracted from patients with severe congenital neutropenia (SCN) respond to priming treatments ahead of administering a CRISPR-based therapeutic.

ELANE-related SCN, also known as SCN1, is a rare, autosomal dominant disease in which a mutation occurs in one allele of the ELANE gene, thereby preventing HSCs from differentiating into white blood cells, specifically neutrophils, which leaves the patient highly susceptible to recurrent bacterial infections, osteoporosis, developmental delays and abnormalities.

Patients with SCN often suffer from reduced quality of life due to the lack of improvements in the standard of care, said Dr. David Rawlings, Division Chief of Immunology at Seattle Children's Hospital and Director of the Center for Immunity and Immunotherapies at Seattle Childrens Research Institute. These children are immunocompromised, and, as a result, we feel a great sense of urgency to ensure were exploring all possible avenues towards a solution.

Seattle Childrens collaboration with Emendo, utilizing its unique approach to edit only the mutated allele with CRISPR, will enable us to address the unmet needs of SCN at the very core, added Rawlings, who also serves as a professor of pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine. Were excited about this opportunity, and look forward to continuing the collaboration beyond this initial study.

Editing the mutated ELANE gene with CRISPR first requires overcoming a technological hurdle: Only the mutated allele must be targeted, while the healthy allele remains intact. Emendo engineered its roster of next-generation CRISPR nucleases to be biologically active and so specific that they can differentiate between two alleles of the same gene. EMD-101, Emendos lead therapeutic candidate for SCN, was specifically engineered to target the mutant ELANE allele.

HSCs have been widely studied as a treatment for sickle cell anemia and cancer, as well as a potential therapy to treat organ and tissue damage. However, HSCs require initial priming prior to stem cell transplantation, which is typically done by administering G-CSF (granulocyte colony stimulating factor). Yet, the same drug is also a short-term treatment for SCN patients.

To better understand how SCN patients would respond to a priming dose of G-CSF and plerixafor, Emendo will evaluate the mobilization of HSCs excised from a small group of patients with SCN, which would be gene-edited later. Concurrently, Seattle Childrens will evaluate the composition of the HSCs obtained from the same patients. Prior mouse studies conducted by Emendo have shown that human cells edited to excise the disease-causing ELANE allele sufficiently engrafted and replaced existing diseased cells, restoring proper neutrophil differentiation.

By combining our allele-specific genome editing technology with Seattle Childrens renowned expertise in SCN spearheaded by Dr. Rawlings we are laying the foundation for future clinical trials that could lead to potential therapies to treat the disease, said David Baram, Ph.D., CEO of Emendo. Our portfolio of engineered nucleases tailored to any gene or allele gives us the unique opportunity to tackle the inherent challenges of SCN. Through this collaboration well be able to provide stronger evidence and further proof points for the capabilities of our technology.

Based on the outcome of the research, a protocol for a clinical trial could be developed with an expected initiation in late 2022, pending regulatory approval. Seattle Children's has certain preferred rights to serve as a clinical trial site.

About Emendo Biotherapeutics

EmendoBio is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. EmendoBios novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide EmendoBio with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit us at http://www.emendobio.com.

About Seattle Childrens

Seattle Childrens mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Childrens Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top childrens hospitals in the country by U.S. News & World Report, Seattle Childrens serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any childrens hospital in the country. As one of the nations top five pediatric research centers, Seattle Childrens Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Childrens Foundation works with the Seattle Childrens Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Childrens bold initiative It Starts With Yes: The Campaign for Seattle Childrens to transform childrens health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.

See the rest here:
Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe...

As 2021 draws to a close, COVID-19 remains a pervasive influence over life at Yale and across the world. And yet, even as a new surge in cases portends a winter of uncertainty, a look back at the past year offers many reminders of just how much more we now know about this global threat, the remarkable importance of vaccines and other public health measures, and the resiliency of humankind.

After reviewing the many hundreds of stories published on Yale News this year, we identified several about Yales response to the pandemic that especially resonated with readers and that best capture how the university and our experts have helped make sense of and respond to this disruptive disease. Youll find a list below.

In a second list below, we highlight several non-COVID stories about the people and projects that inspired us and gave us hope for a healthier and more equitable 2022 and the new initiatives that will position the Yale community to be a leader in tackling the challenges of the future.

As the new year began, Yale News reviewed how the campus community pulled together to do the work of the university in the face of unprecedented challenges, and looked ahead to the spring semester.

As chair of the White Houses COVID-19 Equity Task Force, Dr. Marcella Nunez-Smith, the C.N.H Long Professor of Internal Medicine, Public Health, and Management at Yale, became a national voice on racial inequities in COVID-19 treatment and outcomes. Meanwhile, Abbe Gluck, the Alfred M. Rankin Professor of Law and professor of internal medicine at Yale School of Medicine, was named special counsel to the Biden administrations COVID-19 Response team. She also worked in the Office of White House Counsel on other health care issues, including the Affordable Care Act..

In early January, Yale launched its COVID-19 vaccination program in the Lanman Center at Payne Whitney Gymnasium, as vaccines from Moderna and Pfizer gained final approvals for use in the United States.

After spending nearly a year cataloguing and exploring the SARS-CoV-2 genomes intricate makeup, a team of Yale scientists revealed a map of it with an unprecedented level of detail, including more than 100 identifiable structures.

In February, Yale scientists developed a new class of antiviral agents that showed promise for creating COVID-19 therapeutics exhibiting particular effectiveness when used in tandem with the drug remdesivir, another antiviral medication approved for use against the virus.

For most children, COVID-19 infection results in a relatively mild illness. In a few cases, however, a severe immune reaction occurs. During the spring, Yale research found that such rare, life-threatening reactions may be triggered by high levels of alarmins, molecules that make up part of the innate immune system.

The Lanman Center, which early in the pandemic was converted into a field hospital, and later into Yales primary vaccination center, returned to being simply a gym during the summer, as the vaccination operations were shifted to the Rose Center on Ashmun Street.

In July, a Yale-led study found that the COVID-19 vaccination campaign launched in the United States in late 2020 had, at that point, saved some 279,000 lives and prevented 1.25 million hospitalizations. Researchers warned, however, that these gains could be reversed by the highly transmissible Delta variant.

In September, Yale researchers provided important insights into what were then becoming known as breakthrough COVID-19 cases in which fully vaccinated individuals are infected by SARS-CoV-2 and which populations are particularly vulnerable to serious breakthrough illness.

Since the start of the COVID-19 pandemic, scientists had been unclear about how long immunity lasts after an unvaccinated person is infected. In October, a Yale-led team of researchers found an answer: Strong protection following natural infection is short-lived, lasting as little as three months or less.

In October, a Yale-led study found that two of the commonly used COVID-19 vaccines provide protection against multiple variants of the virus that causes the disease, including the highly infectious Delta variant. Their findings also showed that those infected with the virus prior to vaccination exhibit a more robust immune response to all variants than those who were uninfected and fully vaccinated.

In November, a study by Yale political scientists and public health experts found that, when it comes to persuading people to get vaccinated against COVID-19, its more effective to appeal to community spirit than to self-interest.

Breakthrough SARS-CoV-2 infections tend to be mild, but Yale research published in December showed that more older adults have developed severe breakthrough cases during the Delta variant phase of the pandemic, particularly after a longer period of time had elapsed since their last vaccination. The findings, researchers say, reveal the importance of booster vaccinations.

White evangelical Christians have resisted getting vaccinated against COVID-19 at higher rates than other religious groups in the U.S. In November, a Yale study found that persuading these vaccine holdouts had only become more difficult.

In December, as a new COVID-19 variant, Omicron, began to spread throughout the world, public health leaders scrambled to better understand how contagious the new variant is and whether existing vaccines are effective against it. Yale doctors offered insights into the emerging threat.

In February, Yale announced the establishment of the Wu Tsai Institute, an ambitious new research enterprise that will supercharge Yales neuroscience initiative and position the university to reveal the brain in its full, dynamic complexity, thanks to a historic gift from Joseph C. Tsai 86, 90 J.D. and his wife, Clara Wu Tsai.

As a historic renovation of the Peabody Museum proceeds, conservator Mariana Di Giacomo is charged with keeping a close eye on the iconic mural The Age of Reptiles, by celebrated artist Rudolph Zallinger. The experience has allowed her to appreciate layers of detail. In February, Yale News caught up with her and shared a dazzling gallery of images.

In a promising early trial, researchers from Yale reported in February that patients with spinal cord injuries experienced substantial improvements in motor function such as the ability to walk or to use their hands after an intravenous injection of bone marrow-derived stem cells.

After 30 months of renovations, the redesigned Humanities Quadrangle formerly the Hall of Graduate Studies put a vibrant new face on Yales longstanding excellence in the humanities. The refurbished building includes dynamic spaces that promote connections among departments and programs and the cultivation of new ideas.

The late Jeremy Ayers once known as the gender-bending performance artist Silva Thin may seem like an unlikely namesake for an ant. But thanks to Yale ecologist Douglas B. Booher and rock star Michael Stipe, who shared a decades-long friendship with Ayers, a new species from the forests of Ecuador will honor his legacy and his reverence for the diversity of life.

During the summer, the university announced that present and future students at Yale Universitys drama school will no longer pay tuition, thanks to a landmark $150 million gift from entertainment executive and philanthropist David Geffen.

Psilocybin, a psychedelic drug found in some mushrooms, has long been studied as a potential treatment for depression. Yale research published in July detailed exactly what happens in the brain after a dose of psilocybin, and what makes its medicinal properties so promising.

In August, Yale scientists published a study of atmospheric patterns on Mars and Saturns moon Titan that will help lay the foundation for more accurate forecasts of weather on other worlds. Researchers say such forecasts will be vital to the safety and success of future research missions.

In 1965, Yale scholars created a sensation with the revelation of the Vinland Map, which was thought to be the earliest known European depiction of the New World. This summer, a team of Yale researchers said it proved the map to be an elaborate 20th-century forgery.

In October, a series of performances by the Yale Glee Club, Yale Bands, and the Yale Symphony Orchestra held in each of Yales residential college courtyards marked a return to live music on campus following a year of lockdowns and a response to the Black Lives Matter protests of 2020. (With video.)

In November, Yale and the City of New Haven reconfirmed their historic, three-century partnership for a new generation, announcing a six-year commitment that increases the universitys annual voluntary financial contribution to the city and creates bold opportunities for inclusive economic growth that benefit the entire community.

Tony Reno, now in his ninth season as head coach of the Yale football team, is more focused on creating a culture of responsibility, camaraderie, and integrity than on wins and losses but that hasnt kept the Bulldogs from finding success on the field.

On the long road to Yale College, Obed Gyedu-Larbi labored as a domestic aide and Greyhound baggage handler. He also founded a non-profit to feed and clothe homeless people in New York City. For me, he said, it was important to not only work hard for myself.

Continued here:
2021: The year in review | YaleNews - Yale News